Catalent Applied Drug Delivery Institute Partners with AAPS on 3rd Annual Global Academic Competition - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Catalent Applied Drug Delivery Institute Partners with AAPS on 3rd Annual Global Academic Competition
Competition seeks to encourage academic research and accelerate drug delivery applications.

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 2

Catalent Applied Drug Delivery Institute’s “3rd Annual Global Academic Competition for Life Science Leaders of Tomorrow,” in collaboration with the American Association of Pharmaceutical Scientists (AAPS) is now open for entries at www.drugdeliveryinstitute.com/global-academic-competition. The aim is to foster an interest in drug delivery among university students enrolled in pharmaceutical sciences, industrial pharmacy, drug delivery, drug development, or other related courses. Participating universities in the US include, St. John’s, Rutgers, New Jersey Institute of Technology, and University of North Carolina at Chapel Hill. In Europe, participating universities include Saarland and Düsseldorf, Germany and Bath and Bristol in the UK. /p>

Participants will compete for one of five prizes of $2,000, a complimentary, one-year AAPS membership, and the opportunity to have their submissions published by Catalent in the Institute and/or industry publications. Articles submitted should be original and based on topics such as drug development, improving therapeutic profiles and bioavailability, pre-formulation, drug delivery innovation in inhalation, biologics, lipid-based systems, crossing the blood-brain barrier, or on the delivery of drugs in certain patient groups such as pediatrics. The deadline for entries is March 28, 2014. More details on the competition, including entry forms and contest rules can be found here.

Source: Catalent Applied Drug Delivery Institute

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here